First and second trimester serum screening
Maternal serum screening tests use a blood sample from the mother to identify pregnancies at risk for certain birth defects
While serum screening has been in use for more than 40 years, noninvasive prenatal screening (NIPS/NIPT) was introduced in 2011 (with our own test, MaterniT 21, being the first commercially available NIPS/NIPT). Both tests are noninvasive (i.e. they require a blood sample from the mother’s arm, not tissue from the placenta or fluid from the amniotic sac).
However, serum screening typically screens for just three common birth defects—Down syndrome, trisomy 18 and open neural tube defects—whereas NIPS (NIPT) can screen for many more defects, as well as fetal sex. Additionally, MaterniT 21 PLUS has higher detection rates than serum screening.
*According to several large, multi-center studies
In addition to serum screening, we offer noninvasive prenatal screening (NIPS/NIPT) for Down syndrome and other conditions; carrier screening for disorders such as cystic fibrosis; diagnostic testing options for post-pregnancy or further confirmation of screening tests; and hereditary cancer screening.